Call for abstracts: FDA Workshop on Computational Modeling for Cardiovascular Devices

Important dates:

Deadline for abstract submissions: April 1, 2009 Notification of acceptance or rejection: April 20, 2009 Workshop dates: June 1-2, 2009

Overview:

All workshop participants are welcome to contribute abstracts. Your submission should state whether you wish to be considered for a poster exhibit, podium presentation, or both. All participants are encouraged to submit abstracts in the themes mentioned below. There is no limit on the number of abstracts submitted by an individual.

Abstract/poster themes:

Theme 1: Device specific research (i) Stent grafts (ii) Drug-eluting or bare metal stents (iii) Heart valves (iv) Ventricular assist devices (v) Cardiac rhythm management

Theme 2: Multi-scale modeling

Theme 3: Imaging for cardiovascular device modeling (i) Image acquisition techniques (ii) Image processing techniques (iii) Application to device design and evaluation

Theme 4: Data for cardiovascular device modeling (i) Validation and verification of computational methods (ii) Evaluating safety and effectiveness of a device (iii) Standards and benchmarking (iv) Testing normal-failure modes (v) Developing best practices in computational modeling

Submission guidelines:

We appreciate your cooperation in adhering to the guidelines outlined below. To ensure that the abstract receives proper scientific consideration, please make sure that it is submitted to the appropriate categories listed above. The following guidelines were established to ensure uniformity between the abstracts for our scientific program. I. FONT: 12 pt Times New Roman, unless other wise stated. II. Margins should be no smaller than 1-inch all around. III. The complete abstracts (excluding titles and authors) for both scientific talks and posters should be limited to 2500 characters (including spaces) or less. IV. The title should be in CAPS, no more than 15 words and no abbreviations V. Please list authors as shown on the template. Please underline the name of the author who will present the material at the meeting, either by podium or poster. VI. Please list affiliations in 10 pt font and as shown on the template: department, university, city, state VII. Please divide your abstract into the following headings: BACKGROUND, METHODS, RESULTS, DISCUSSION, and REFERENCES (optional) VIII. You may include a figure in the abstract. However, the abstract should NOT exceed 1-page. We will not accept abstracts longer than one page. IX. You may submit in .pdf, .doc or .docx formats, but the file size should not exceed 2 MB. X. Submitted your abstract electronically to the following URL: http://www.blsmeetings.net/FDA_CMCVD/

Once you have submitted your abstract, you will receive confirmation by email that your abstract has been received. Abstracts will be evaluated both on their contributions and on how effectively they communicate those contributions. Once the proposals are submitted, they cannot be modified. Upon acceptance, the authors will be notified by email. For additional information, clarifications, or questions, please contact the workshop committee at cpi.cmcvd@fda.hhs.gov.

Program Committee:

Donna Lochner, B.S., FDA/ODE Charles Taylor, Ph.D., Stanford University Elazer Edelman, M.D., Ph.D., MIT Timothy Baldwin, Ph.D., NHLBI Bram Zuckerman, M.D., FDA/ODE Laurence Grossman, Ph.D., FDA/OSEL Semahat Demir, Ph.D., NSF